Definium Therapeutics (NASDAQ:DFTX) Stock Rating Lowered by Wall Street Zen

Definium Therapeutics (NASDAQ:DFTX) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Saturday.

A number of other research analysts also recently commented on the stock. Piper Sandler reiterated an “overweight” rating and set a $48.00 price objective (down from $49.00) on shares of Definium Therapeutics in a research note on Friday, May 8th. Royal Bank Of Canada reissued an “outperform” rating on shares of Definium Therapeutics in a report on Monday, June 22nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Definium Therapeutics in a research report on Tuesday, April 21st. Canaccord Genuity Group set a $58.00 target price on shares of Definium Therapeutics and gave the company a “buy” rating in a research note on Tuesday, June 30th. Finally, Needham & Company LLC increased their price target on shares of Definium Therapeutics from $38.00 to $50.00 and gave the stock a “buy” rating in a research report on Tuesday, June 23rd. Two analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $49.23.

Definium Therapeutics Price Performance

DFTX stock opened at $44.29 on Friday. The stock’s 50 day moving average is $31.43 and its two-hundred day moving average is $22.83. Definium Therapeutics has a 52-week low of $7.96 and a 52-week high of $49.20. The company has a market capitalization of $4.42 billion, a PE ratio of -17.79 and a beta of 2.20. The company has a quick ratio of 4.69, a current ratio of 4.69 and a debt-to-equity ratio of 0.15.

Definium Therapeutics (NASDAQ:DFTX) last released its earnings results on Friday, May 8th. The company reported ($0.71) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.23). Analysts predict that Definium Therapeutics will post -2.27 earnings per share for the current fiscal year.

Insider Transactions at Definium Therapeutics

In other Definium Therapeutics news, insider Mark Sullivan sold 13,008 shares of the business’s stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total transaction of $585,750.24. Following the completion of the sale, the insider owned 320,571 shares in the company, valued at $14,435,312.13. The trade was a 3.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Robert Barrow sold 29,208 shares of the stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $45.03, for a total transaction of $1,315,236.24. Following the sale, the chief executive officer directly owned 1,098,246 shares in the company, valued at $49,454,017.38. This trade represents a 2.59% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 48,096 shares of company stock valued at $2,165,763. 2.40% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of DFTX. Commodore Capital LP grew its position in shares of Definium Therapeutics by 10.5% during the 2nd quarter. Commodore Capital LP now owns 5,000,000 shares of the company’s stock valued at $32,450,000 after buying an additional 475,000 shares during the last quarter. Vanguard Group Inc. raised its stake in Definium Therapeutics by 11.0% during the third quarter. Vanguard Group Inc. now owns 2,012,874 shares of the company’s stock worth $23,732,000 after acquiring an additional 198,878 shares during the period. UBS Group AG lifted its holdings in Definium Therapeutics by 7.3% in the third quarter. UBS Group AG now owns 551,809 shares of the company’s stock worth $6,506,000 after acquiring an additional 37,364 shares during the last quarter. Orbimed Advisors LLC bought a new position in Definium Therapeutics in the third quarter worth about $4,337,000. Finally, Millennium Management LLC boosted its stake in Definium Therapeutics by 62.6% in the third quarter. Millennium Management LLC now owns 298,205 shares of the company’s stock valued at $3,516,000 after acquiring an additional 114,805 shares during the period. 27.91% of the stock is currently owned by institutional investors.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.